#CannesLions2022: Addressing clinical trial diversity problems will take 'real work now,' panelists say
CANNES — As a young scientist, Sommer Bazuro was looking at oncology data when she realized that the patient population was not at all representative of the demographics most likely to suffer and die from cancer.
Thinking it must be an isolated incident, she turned to peer-reviewed publications and began talking to oncologists, only to discover that a lack of diversity in clinical trials was par for the course. Black and Hispanic patients typically don’t even reach levels of representation consistent with the general population.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.